Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELZ |
---|---|---|
09:32 ET | 975 | 4.8 |
09:38 ET | 158 | 4.6 |
09:39 ET | 210 | 4.7714 |
09:52 ET | 842 | 4.6 |
10:24 ET | 500 | 4.5 |
10:33 ET | 100 | 4.53 |
11:04 ET | 500 | 4.6926 |
11:22 ET | 100 | 4.54 |
11:29 ET | 255 | 4.54 |
11:40 ET | 334 | 4.54 |
11:42 ET | 100 | 4.5201 |
11:49 ET | 100 | 4.52 |
12:03 ET | 200 | 4.52 |
12:20 ET | 250 | 4.5296 |
12:21 ET | 2049 | 4.52 |
12:23 ET | 100 | 4.5111 |
12:45 ET | 4029 | 4.52 |
01:15 ET | 500 | 4.5 |
01:17 ET | 133 | 4.4 |
01:26 ET | 252 | 4.485 |
01:57 ET | 1000 | 4.4622 |
02:13 ET | 100 | 4.46 |
02:26 ET | 2037 | 4.4939 |
02:31 ET | 250 | 4.4276 |
03:18 ET | 100 | 4.35 |
03:32 ET | 966 | 4.4 |
03:41 ET | 681 | 4.45 |
03:45 ET | 308 | 4.4465 |
03:50 ET | 100 | 4.4 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Creative Medical Technology Holdings Inc | 6.5M | -1.2x | --- |
Kazia Therapeutics Ltd | 10.3M | -0.5x | --- |
ProtoKinetix Inc | 6.6M | -12.5x | --- |
Theriva Biologics Inc | 6.3M | -0.4x | --- |
Enveric Biosciences Inc | 6.8M | -0.1x | --- |
eFFECTOR Therapeutics Inc | 6.8M | -0.1x | --- |
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.5M |
---|---|
Revenue (TTM) | $9.0K |
Shares Outstanding | 1.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 5.04 |
EPS | $-3.76 |
Book Value | $7.53 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 725.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -62,446.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.